Antigen-specific B-Cell Enrichment (Reactivation)
What is Reactivation?
Reactivation is NeoClone's patented process to reactivate antigen-specific lymphocytes for antibody development. We have established specific culture conditions which enrich for class-switched, high affinity B cells over non-target cells. Our platform captures desired affinity characteristics and the diversity of the B cell response.
Basic Enrichment Process
- Selection of activated lymphocytes
- Culture in supportive media
- Expansion of antigen-specific Ig -secreting cells
- Reduction of non-specific Ig-secreting cells
- Long-term culture
Sample ELISPOT examining total murine splenocytes (top row) and the enriched B-cell population (bottom row). Wells were coated with specific antigen (left 2 columns), an irrelevant antigen (middle 2 columns) or total IgG (right 2 columns) and the cell populations were incubated in the wells in duplicate.
Antigen-Specific Human B-Cell Enrichment
It turns out that murine B cell reactivation technology is a natural fit for transgenic mouse companies seeking high quality, fully human antibodies. In 2012, the National Institutes of Health awarded NeoClone Biotechnology a grant for the project: “Reactivation of human cells for novel fully human Ab platform”. The Principal Investigator was Rachel Kravitz, PhD, NeoClone’s Director of Research.
Neoclone’s hu-mAb platform (which has been marketed under the NeoAb® process) offers several advantages over existing technologies;
- The mAbs are fully human, having been developed from human immune cells in a SCID mouse model.
- The approach does not require immunizing patients or access to convalescent blood, therefore the platform is amenable for mAb development using de novo immunization against any therapeutic target.
- mAbs developed using this approach will likely have higher affinities than Abs generated by library-based methods since reactivation focuses on selection of affinity-matured cell targets that proliferate in very low Ag levels.
- hu-mAbs generated using the NeoAb® process can have fully-human glycosylation patterns, a distinct advantage over human mAbs expressed in non-human cells.
In addition, this process enables NeoClone to select for or against certain secondary characteristics such as Ab-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC). Thus, Neoclone’s approach to hu-mAb production can circumvent the limitations of current technologies, and promote development of new therapeutic treatments by lowering the costs of fully-human mAbs.
NeoClone's hu-mAb platform increases the number of class switched, affinity matured, antigen specific B cells, while eliminating all other cell types in the process. This can potentially be a strong candidate process to work in transgenic mouse models as well. NeoClone is currently exploring collaborations with transgenic mouse companies looking for a robust method to increase the number of cells producing fully-human antigen specific antibodies.
Market Requirements for Therapeutic antibodies
- Fully human (Fewer safety issues / better efficacy)
- Diversity (Need to deliver multiple good candidates for client evaluation)
- Affinity (Need to deliver candidates with a range of affinities to allow for the selection of the most appropriate antibodies)
- Specific (de novo immunizations)
- Reproducibility - Quality (Need to generate an appropriate number of candidates each time)
- Reasonable Timeframe (Quickly to market)
NeoClone's platform technology has the potential to generate fully human, high affinity hu-mAbs at an affordable price. This proprietary approach provides an economical solution for developing high affinity hu-mAbs for biotech & pharmaceutical companies as well as academic researchers interested in reagents for pre-clinical trials.
If you are interested discussing how we can help you in developing the very best therapeutic or pre-clinical antibodies, contact us today at